Puma Biotechnology Publishes Q3 2026 Commercial Update Presentation

Bitget2026/11/05 23:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Puma Biotechnology reported third-quarter 2026 net NERLYNX revenue of $54.1 million, up approximately 5% year over year.
Revenue rose approximately 1% from the second quarter.
Ex-factory sales totaled 2,818 bottles, down approximately 4% both year over year and sequentially.
U.S. commercial demand reached 2,899 bottles, up approximately 5% year over year but down approximately 3% sequentially.
Inventory declined $1.5 million, compared with a $1 million decline in the second quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Puma Biotechnology Publishes Q3 2026 Commercial Update Presentation

You may also like

Crypto prices